StockData

Carlsmed vs Treace Medical Concepts

CARL and TMCI side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How CARL and TMCI compare

Carlsmed is the larger company, worth 1.4 times as much as Treace Medical Concepts ($467M against $343M).

Carlsmed grew revenue faster over the last twelve months (60.4% versus −7.1% for Treace Medical Concepts).

Treace Medical Concepts keeps more of each dollar of sales as profit, with a net margin of −27.4% compared with −55.8% at Carlsmed.

Carlsmed scores higher on the StockData Score (5 against 4 for Treace Medical Concepts), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricCARLTMCI
Size and price
Market cap$467M$343M
Share price$17.12$5.27
Change, 1 year38.7%58.5%
Change, 5 years–−73.1%
Beta (5Y)2.181.70
Employees24450
StockData Score
Total score5 (better)4
Valuation score01 (better)
Growth score3 (better)1
Performance score00
Health score22
Dividend score00
Valuation
P/S6.5×1.7× (better)
P/B6.2×5.6× (better)
FCF yield−7.5%−5.4% (better)
Fair value$8.07$6.26
Margin of safety−112%15.9% (better)
Growth
Revenue growth (TTM)60.4% (better)−7.1%
Revenue growth, 5Y average–30.0%
Profitability
Gross margin77.0%79.6% (better)
Operating margin−59.0%−24.4% (better)
Net margin−55.8%−27.4% (better)
FCF margin−48.6%−9.1% (better)
Return on equity−43.9% (better)−74.0%
Return on invested capital−953%−46.4% (better)
Financial health
Debt / equity–0.97
Interest coverage−33.3×−8.2× (better)
Current ratio5.79 (better)2.58
Altman Z-score5.80 (better)0.15
Piotroski F-score6 (better)2
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions20.9%49.0%
Held by insiders81.1%28.0%
Insider net buying, 12 months−$2.7M$1.5M (better)
Short interest, % of float24.0%3.8%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.